Biopharmaceutical News and Research

RSS

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

29 Sep 2011

TD2 wins AZBio's Fast Lane award for economic development of Arizona biosciences

TGen Drug Development (TD2) won a Fast Lane award from the Arizona BioIndustry Association (AZBio) for promoting the economic development of Arizona biosciences.

29 Sep 2011

Halozyme commences HTI-501 clinical trial for cellulite in women

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite).

28 Sep 2011

HealthyWomen launches web-based initiative to manage RA

Managing RA: The Strong Woman's Approach, is an online resource designed to educate and empower women living with rheumatoid arthritis (RA), launched today at HealthyWomen.org.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory Society.

27 Sep 2011

TPI revenue increases 48.9% to $95.2 million for fiscal year 2011

Tianyin Pharmaceutical Co., Inc., a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, announced the financial results for the Fiscal Year 2011.

27 Sep 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost. In the study, non-preserved latanoprost was compared to Xalatan (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.

26 Sep 2011

Shire announces update on approval status and availability of ProAmatine SOH drug

Shire plc, the global specialty biopharmaceutical company, announces an update on the approval status and availability of ProAmatine (midodrine HCl), a medicine approved for the treatment of symptomatic orthostatic hypotension.

23 Sep 2011

Palatin's fourth quarter net loss decreases to $3.3 million

Palatin Technologies, Inc., a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.

22 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Millennium ranked fifth among best biopharmaceutical companies in the world

Millennium: The Takeda Oncology Company today announced that Science magazine has named it among the best biopharmaceutical companies in the world for the fourth consecutive year. Each year Science conducts a survey to determine the top employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries worldwide.

17 Sep 2011

InNexus Biotechnology announces incentive stock options

InNexus Biotechnology Inc., a biopharmaceutical company creating and developing innovative solutions for cancer, inflammation and other difficult-to-treat diseases, announces that it has, effective August 26, 2011, granted incentive stock options to purchase an aggregate of 1,068,683 common shares without par value in the capital of the Company to certain persons who are either a director, officer, employee or consultant of the Company.

17 Sep 2011

President's signing of America Invents Act a huge win for innovators

Today's historic signing of the America Invents Act represents a huge win for innovators and improves U.S. competiveness globally by aligning new patent laws more closely with those from other countries, said John Lechleiter, Ph.D., Chairman, President and Chief Executive Officer of Eli Lilly and Company.

17 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536.

14 Sep 2011

Biopharmaceutical News and Research

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

TD2 wins AZBio's Fast Lane award for economic development of Arizona biosciences

Halozyme commences HTI-501 clinical trial for cellulite in women

HealthyWomen launches web-based initiative to manage RA

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

Elevation presents positive data from EP-101 Phase 2a study on COPD at ERS annual meeting

TPI revenue increases 48.9% to $95.2 million for fiscal year 2011

Positive results from Clermont's non-preserved latanoprost phase III trial on glaucoma

Shire announces update on approval status and availability of ProAmatine SOH drug

Palatin's fourth quarter net loss decreases to $3.3 million

Tokai raises $23M in Series D3 financing

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Powerful new antibiotic treatment for MRSA and C. difficile bugs

Millennium ranked fifth among best biopharmaceutical companies in the world

InNexus Biotechnology announces incentive stock options

President's signing of America Invents Act a huge win for innovators

Teva to invest in CDI for development of novel antiviral drugs

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Lexicon's LX4211 clinical data presented at EASD annual meeting

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

Biotechnology eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News